celgene stock Investors are panicking over Celgene's new long term sales guidance Thursday. 's stock appears to be on the mend after falling by more than 40% since October. 79 in 2018 Q1. Celgene Corp (NAS:CELG) Stock Analysis, 10 Years Financial Analysis, Interactive Charts, Stock Valuations, Value Investing CELG – analyst ratings, historical stock prices, earnings estimates & actuals for Celgene Corp. 51% with the market. Trend analysis of basic items. Covering U. Celgene (CELG) reports earnings on 10/25/2018. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze. CELG stock history. Visit PayScale to research Celgene Corporation salaries, bonuses, reviews, and benefits. Updated key statistics for Celgene Corp. com: The #1 Source For Dividend Investing Stock quote for Celgene Corporation Common Stock Common Stock (CELG) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Analysts have a mean recommendation of 2. CELG (Celgene Corp) Stock – Morningstar stock analysis including quotes, news, returns, research and ratings, as well as charts, financial statements, and ownership information. Celgene stock analysis, Celgene valuation, PE Ratio, Celgene stock rating and financial analysis. Including historical share prices, analysis, earnings, cash flow and market valuation for Celgene Corp. " CELG Disclosure of Celgene's Liabilities and Stockholders' Equity from Statement of Financial Position. 9 billion in cash and stock to acquire Pharmion, strengthening Celgene’s cancer drug portfolio and its distribution in Europe. Loughlin sold 17,750 shares of the business’s stock in a transaction dated Monday, June 4th. com. Celgene share price history. Celgene Corporation (CELG) belonging to the Healthcare sector has declined -0. Signup for a free trial today! Celgene stock (881244 | US1510201049). All stock splits for CELG have also been listed. 38 million shares in 2017Q4 An audit of Celgene’s R&D over the last five years has revealed that two-thirds of its programs failed. 72 Long term trend is Celgene Corporation (NASDAQ:CELG) is a company in the Major Pharmaceuticals industry and Consumer Durables sector. 26% based on its latest 2018Q1 regulatory filing with the SEC. chart and CELG price. Weekly Pivot: $0 Short term trend is Up. Celgene #189 on the Forbes Growth Champions List News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the startup. What Stock Options benefit do Celgene employees get? Celgene Stock Options, reported anonymously by Celgene employees. Currently, the stock has a 1 Celgene Corporation (CELG) stock predictions, analysis, quotes, charts, portfolios, trading systems and artificial intelligence. S stock quotes on the dow jones industrial average and nyse. The Committee will, with regard to each stock option, determine the number of shares subject to the option, the term of the option (which shall not exceed ten years, provided, however, that the term of an incentive stock option granted to a 10% The pharmaceutical company Celgene has agreed to pay $280 million to settle claims that it marketed the cancer drugs Thalomid and Revlimid for unapproved uses, the company said on Tuesday. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. , placing a costly bet on cutting-edge cancer treatments. View the basic CELG stock chart on Yahoo Finance. Description of the stock CELG, Celgene Corp, from Dividend Channel. August 09, 2018, BY Thomas H. See charts, data and financials for Celgene Corp CELG Stock analysis for Celgene Corp (CELG:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View the latest CELG stock quote and chart on MSN Money. Stock screener for investors and traders, financial visualizations. Join Celgene's Talent Community to be notified automatically when positions that match your passions become available. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. stock price, stock quotes and financial overviews from MarketWatch. Celgene Corp. Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion. You might think it's a crazy idea. A quick analysis of Celgene Corporation (NASDAQ: CELG) stock history reveals three distinct stages with four stock splits along the way. Read news, commentary, analysis and events related to CELGENE CORPORATION (CELG). CELGENE $CELG Technical Update. In the second episode of Stock Picking with Maylan Studart, Celgene is in the spotlight. Change the date range, chart type and compare Celgene Corporation against other companies. 96, for a total transaction of $1,401,540. Buy and sell Celgene Corp on eToro. The average salary for Celgene Corporation employees is $106,000 per year. View Celgene Corporation CELG investment & stock information. Stock Options. I reviewed the charts of CELG at the end of May, and I noted that "CELG has already made a short-term reversal by closing above the high of the low day Free real-time stock charts for Celgene Corp (CELG). com Are you considering adding Celgene (NASDAQ:CELG) stock to your your portfolio? View CELG's stock price, price target, analyst ratings, earnings history, financials, history, insider trades, news headlines and SEC filings in real-time at MarketBeat. Granted, there's a big hurdle with a deal such as this. Get detailed information about the dividend date and dividend announcements for Celgene. Celgene agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Cohen Klingenstein LLC bought a new position in shares of Celgene Co. Market Capitalization data for Celgene: industry ranking, historical trend, and competitor comparison Celgene Corporation Earnings Surprise. Kee Jr - Editor, Stock Traders Daily | Subscribe to RSS The CELGENE (NASDAQ: CELG) update and the technical summary table below can help you manage risk and optimize returns. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. made one of its largest deals ever with the $9 billion acquisition of Juno Therapeutics Inc. 8% since reporting last quarter. The charts and indicators of Celgene Corp. 73 per share, with a total value of $500,244. It is incorporated in Delaware and headquartered in Summit, New Jersey. (NASDAQ:CELG) Director John H. What are top-rated research analysts are saying about Celgene (NASDAQ:CELG)? View CELG's most recent analyst ratings, recommendations and price targets at MarketBeat. But sometimes crazy ideas are the ones that wind up being the best. S. Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. Traders were woefully unhedged for Celgene's 20% stock drop following a disastrous earnings report that saw the company miss on sales and cut forward guidance. Get the latest Celgene Corporation CELG detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases. increased its stake in shares of Celgene Co. Analyze performance using advanced charting and trend analysis. Morgan Healthcare Conference. The Celgene Corporation stock performance guide calculates the current value and returns of CELG stock for different time periods assuming all dividends have been reinvested. I am in no rush to probe the long side again. Find the latest news, stock prices and financial information for Celgene on Fortune. Read CELG related news and find out why Celgene’s (CELG) news sentiment is more negative in relation to stocks in the Healthcare sector. The institutional investor bought 13,240 shares of the biopharmaceutical company’s stock, valued at approximately $1,052,000. 59% less from 561. Real-time trade and investing ideas on Celgene Corporation CELG from the largest community of traders and investors. A free inside look at company reviews and salaries posted anonymously by employees. Shares are up 1. Celgene Corporation (CELG) Pre-Market Trading - View free premarket stock trades at NASDAQ. Check if Celgene stock listed on NASDAQ is one among top stocks to buy. AWS provides cloud computing services to hundreds of thousands of customers. stock price. Celgene has underperformed both SPY and IBB in the last three years. . Stock quote and company snapshot for CELGENE CORPORATION (CELG), including profile, stock chart, recent news and events, analyst opinions, and research reports. Top Dividend Stocks. View Celgene Corporation (NASDAQ: CELG) stock data and charts on Benzinga. 513. Get the latest price and volume on Celgene Corp in IBD stock charts. The company beat on earnings per share and revenue expectations. CELG's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend. Latest Celgene Corp (CELG:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts. The Morning Consult Brand Index is an indicator of brand strength among consumers. The Investor Relations website contains information about Celgene Corporation business for stockholders, potential investors, and financial analysts. 04, from 0. The shares were purchased at an average price of $89. On Thursday before the open, Celgene Corporation (NASDAQ:CELG) reported its fourth-quarter earnings results. It's usually unwise to call any single earnings report a do-or-die event, but for troubled Celgene (CELG), Friday’s first-quarter financial update comes pretty close. It dropped, as 120 investors sold Celgene Corporation shares while 470 reduced holdings. - including celg margins, P/E ratio, valuation, profitability, company description, and other stock analysis data. Our investment research resources are provided to help you make informed investment decisions. 10% yoy. Dive deeper with interactive charts and top stories of Celgene Corp. The stock i Celgene shares have traded mixed since reporting earnings. 200 day moving average: $125. Updated stock price target summary. 1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Most stock quote data provided by BATS. The biotech company Celgene said Sunday that it would pay $2. (NASDAQ:CELG) by 15. (NASDAQ:CELG). View detailed financial information, real-time news, videos, quotes and analysis on Celgene Corp. Should value investors buy Celgene Corporation stock? (CELG) share price, free cash flow, and discounted present value analysis. lifted its holdings in Celgene Co. Learn about working at Celgene. 00 and a low estimate of $93. Celgene said Tuesday that the FDA refused to review its multiple sclerosis drug Ozanimod for approval. 284 Celgene reviews. The biotechnology company has been up more than 20 percent in the la Celgene Corporation Message board - Online Community of active, educated investors researching and discussing Celgene Corporation Stocks. 9 billion. Maybe it is a crazy idea. The biopharma has a plan to earnings growth ignored by the market. View the basic CELG stock information on AOL Finance and compare CELGENE-CORPORATION against other companies stoxline. Latest Celgene Share Price - Live CELG share price quotes, charts, profile, RNS & company financials for NSQ:CELG Despite the lackluster performance since the second half of 2015, I have held on to every single Celgene share that I owned. Just what is going on at Celgene? They've had some odd recent setbacks (such as as the failure of Mongersen), and another such acquisition, Ozanimod, had its Arena Pharmaceuticals (NASDAQ: ARNA) plans to roll out phase 2 results for etrasimod this quarter, and Celgene (NASDAQ: CELG) investors ought to be paying attention. Get Celgene Corporation's stock price today. Celgene Corporation (CELG) stock predictions, analysis, quotes, charts, portfolios, trading systems and artificial intelligence. Detailed Stock Analysis (Performance (YTD , Weekly & Daily), Trends, Stock Chart, Fundamental and Technical Analysis) to Find Best Performing Stocks and ETFs for Investing and Trading Celgene Corporation (CELG) has fallen amid talks that the company will buy Juno Therapeutics Download Celgene stock price history with daily open, high, low, close and volume data for the last 10 years. Morningstar real-time stock quotes, graphs, and independent analysis for CELG keep you informed. Celgene Corp. Celgene's market cap is close to $80 When Mark Alles got the big promotion to CEO of Celgene $CELG two years ago, the company was a widely admired big biotech which had committed large portions of its revenue to building a pipeline through some of the most intense dealmaking activities in the industry. Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors? In other Celgene news, Director James J. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG) in 2018. Ltd. Celgene Corporation (NASDAQ: CELG) is up slightly on the day. SmarTrend delivers real-time stock market technical analysis and stock trend alerts. 05 a piece versus the consensus-estimated $1. com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock market headline news Read the Celgene customer case study, powered by the AWS cloud. Stock Research. Celgene's market cap is close to $80 You might think it's a crazy idea. Current stock price, news, quotes, charts, key data and dates. Celgene Corporation Message board - Online Community of active, educated investors researching and discussing Celgene Corporation Stocks. Juno Therapeutics surged 46% in late trading Tuesday on a report that Celgene is in talks to acquire it. But should investors bail on the biotech stock -- or buy it? Celgene Corporation manufactures, markets and/or distributes more than 8 drugs in the U. Celgene Corporation (NASDAQ:CELG) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share Celgene Corporation | Nasdaq: CELG | Nasdaq Celgene is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. And I don't anticipate selling the stock in the future. Celgene on the Fortune 500 via @FortuneMagazine. Celgene's market cap is close to $80 Doheny Asset Management decreased its stake in Celgene Corp (CELG) by 15. 00. Valuation ratios such as P/E, P/BV, P/S. All times are ET. Latest real-time Bats price quote, charts, financials, technicals and opinions. Stay up to date with Celgene Corp stock price and analyst ratings on Morningstar. Celgene’s shares rose after the biotech company announced an accelerated stock repurchase, but the pace of Celgene’s buybacks shouldn’t do much to reassure investors. These stages led to the company becoming what the New Jersey-based biotech giant Celgene is reportedly in talks to buy Seattle-based biotech Juno Therapeutics, sending Juno’s stock skyrocketing 50 percent. Last updated 2018/07/24 21:12 UTC. (CELG) were reviewed back in March, and I wrote that, "The pace of the decline has slowed on CELG on the daily and the weekly chart but sellers of the stock are still being more aggressive than the buyers. Investors sentiment decreased to 0. Celgene (CELG) stock quote, charts, historical data, financials. Should you invest in Celgene Corporation (NasdaqGS:CELG)? Proven track record with reasonable growth potential. Share. Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation It’s a fairly risky price to pay $9 billion for a company that has much more shaky fundamentals than an similar company which was brought for $11. biotech company's shares down 2 percent. CELG stock quote, chart and news. Biotech giant Celgene is abandoning a drug it bought for $710 million — and the stock is dropping View the latest CELG stock price with Barron's. Celgene tanked nearly 8% late Tuesday after the FDA refused to file its application for a multiple sclerosis treatment called ozanimod. Celgene had a pretty tough fourth quarter in 2017. Celgene's financial ratios grouped by activity, liquidity, solvency, and profitability. Historic data for CELG based on end of day price. 75. 20 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG) LOS ANGELES, Ca. Follow the $CELG chart and receive real-time updates. Complete the form below to receive the latest headlines and analysts' recommendations for Celgene with our free daily email newsletter: Woodstock Corp decreased its holdings in Celgene Co. Celgene Corporation (NASDAQ:CELG) stock is surging on the back of a Trump victory, as investors feared a Clinton Victory. CELG - Celgene Corp. Community Stock Ratings for Celgene Corporation (CELG) - See ratings for CELG from other NASDAQ Community members and submit your own rating for CELG. Celgene made a costly mistake. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno Celgene Corp. A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. com CELG's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend. Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. and hear what the experts at TheStreet are saying about CELG. com: The #1 Source For Dividend Investing CELG - Short squeeze stock short interest data and short selling information for shares of Celgene Corporation. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts. Free real-time prices, trades and chat. (NASDAQ:CELG) by 2,010. Don't miss CELG stock next rating changes Celgene (CELG) and Incyte (INCY) are two stocks bulls should consider after the sell-off, if history is any indicator Celgene Stock Price Forecast, CELG stock price prediction. Celgene Corporation's stock rating is based on fundamental analysis. The fund owned 119,395 shares of the biopharmaceutical company’s stock after purchasing Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases. 18 million shares or 8. Company Name: Celgene Corporation, Stock Symbol: CELG, Industry: Biotechs, Total Posts: 330, Last Post: 7/2/2018 11:08:21 PM I own some of this stock, I think they look very solid. The stock is falling as the result of a failed clinical trial. Under the terms of the settlement, which resulted from a lawsuit filed by a whistle-blower — a former sales Celgene Corp. 66. Compare your broker's rates now to find out if you can save money Mar 14, 2018 06:45 AM RBC Explores a Possible LBO of Celgene (CELG) Mar 13, 2018 04:23 PM Form 4 CELGENE CORP /DE/ For: Mar 12 Filed by: LOUGHLIN JAMES J Get quotes, news, returns, research and ratings, as well as charts, valuations, financial statements, estimates and ownership information on Celgene Corp. The institutional investor owned 2,089 shares of the biopharmaceutical company’s Tokio Marine Asset Management Co. Information about which ETFs are holding the stock CELG, Celgene Corp, from ETF Channel. However, management told a reassuring story and CELG stock is one to buy at these levels. Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Rating Stock volatility using proprietary measures has hit a plunging low level. Claim your 2-week free trial to StreetInsider Premium here. Celgene Corporation (NASDAQ: CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Celgene just lost one of the most important drugs in its research pipeline, a treatment for Crohn's disease, to a late-stage clinical trial blowup. View the latest CELG stock price with Barron's. For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. Company: Celgene Corporation: Buyback: CELG buyback $Amount Authorized: $5,000,000,000 : Buyback Details: Celgene Corporation (NASDAQ:CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock. Long term trend is Celgene Corporation (NASDAQ:CELG) is a company in the Major Pharmaceuticals industry and Consumer Durables sector. CELG's price target is $119. Celgene Corporation (CELG) surprised the stock market in its last reported earnings when it earned $2. Traded as a value company, Celgene does not appear to convincingly show a long-term vision Celgene's fallen out of favor with investors, but drugs currently in development might make buying its shares smart. Free stocks price quote for CELG. Stock quote for Celgene Corporation Common Stock Common Stock (CELG) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Latest stock price today and the US's most active stock market forums. 96. In an acquisition announced last month, Celgene agreed to buy Juno Therapeutics for $9 billion—or $87 per share—to get its hands on the company's promising CAR-T technology. CELG News and research before you hear about it on CNBC and others. Celgene wows yet again at the J. 54 with a high estimate of $163. , and Vodafone all posted new 52-week lows Thursday. stock quote and CELG charts. 106 funds opened positions while 363 raised stakes. Celgene Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: CELG | Nasdaq A stock split history for Celgene and split-adjusted CAGR. 76% and closed its last trading session at $76. (NASDAQ:CELG) by 0. 83 in 2017Q4. See the company profile for Celgene Corporation (CELG), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information. Weiland acquired 5,575 shares of the business’s stock in a transaction on Tuesday, August 7th. See CELG price target based on 17 analysts offering 12 month price targets for Celgene (CELG) in the last 3 months. Learn about career opportunities that turn the impossible into the possible to deliver life-changing results for patients worldwide. P. (NASDAQ:CELG) during the 2nd quarter, according to its most recent disclosure with the SEC. Brand Index Methodology. 1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. Search CELG, Celgene Corp - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines View Celgene Corporation (NASDAQ: CELG) stock data and charts on Benzinga. 'Upon its preliminary review, the FDA&nbs 29 Celgene reviews. Join LinkedIn today for free. Shares of biotech stock Regeneron Pharmaceuticals are lower, while fellow biotech Celgene and dating app Match are pushing higher CELGENE $CELG Technical Update. Doheny Asset Management sold 4,365 shares as the company's stock declined 18. SUBSCRIBE. Options may be in the form of incentive stock options or nonqualified stock options. Celgene Corporation (NASDAQ: CELG) is having a rough start to the trading session in the pre-market hours, and for good reason. " CELG Celgene Corporation is an integrated global biopharmaceutical company. Celgene Corporation (CELG) News – Find the latest company news headlines for Celgene Corporation and all the companies you research at NASDAQ. Celgene stock hit the most oversold technical reading in 16 years and could post double-digit percentage returns in coming months. However, that movement could change at any moment following the circulation of rumors that are hitting the feeds as we speak. Its down 0. 10% in the last 5 years and has earnings rose of 46. Celgene trades at multi-year lows following set backs in some key pipeline drugs. Real time Celgene (CELG) stock price quote, stock graph, news & analysis. Today, its stock price is badly . Stock - CELG news, historical stock charts, analyst ratings, financials, and today’s Celgene Corp. Celgene to pay Prothena $100M upfront, $50M equity investment in collaboration to develop therapies targeting proteins that include tau, TDP-43, and an undisclosed target Celgene to pay Prothena $100M upfront, $50M equity investment in collaboration to develop therapies targeting proteins that include tau, TDP-43, and an undisclosed target Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon. Note Even though Celgene Corporation is a large cap, just the fact that it is a biotechnology pharmaceutical company makes CELG susceptible to excessive risk as the stock may vascillate based on drug trial results, FDA decisions, competitor FDA data, takeover or Migdal Insurance & Financial Holdings Ltd. Get SEC filings for Celgene Corp (CELG), including Annual Report (10k) and Quarterly Report (10Q). Celgene Corp (CELG) Stock Analysis, 10 Years Financial Analysis, Interactive Charts, Stock Valuations, Value Investing Celgene stock is in free-fall mode, down more than 33% so far this year as investors bail on the stock post-earnings. However, enough positive developments have occurred to make CELG stock a buy. co/dqhIpq9L" Celgene, NetEase, PPL Corp. Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Explore commentary on Celgene Corp. A national survey of employees revealed that biopharmaceutical company Celgene is the best employer. (CELG) has suffered a long decline since October, but there is some light at the end of the tunnel if I read the charts correctly. Celgene cut full-year revenue guidance and trimmed its 2020 outlook. See who you know at Celgene, leverage your professional network, and get hired. The latest Tweets from Celgene Stock Report (@CELGStockReport): "$CELG (CELG) Celgene Corporati trading over 200 Day Moving Average 11/28/2011: full article: http://t. The stock was sold at an average price of $78. Celgene is #24 on the 2017 Fortune 500 list. Celgene Co. The best long-term & short-term Celgene share price prognosis for 2018, 2019, 2020, 2021, 2022, 2023 with daily CELG exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis Celgene is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The biotechnology industry has been a huge growth engine for the stock market in recent years, and Celgene (NASDAQ:CELG) stands as one of the biggest players in Celgene Corp. CELG: Get the latest Celgene stock price and detailed information including CELG news, historical charts and realtime prices. Celgene Stock Price History. If you do not have an online account, select Create User Account to establish an account. They have brought on a slew of new people and appear to be setting the stage for commercialization of their first product, a drug for AIDS wasting. A year by year calculation of the yearly returns of Celgene Corporation using the actual trading prices CELG stock was at during each respective year. Celgene Corporation (CELG) have shown a high EPS growth of 17. 7% during the second quarter, according to its most recent filing with the Securities and Celgene Corp , which has announced a deal to buy Impact Biomedicines, on Monday forecast 2018 total revenue that fell short of analysts' estimates, sending the U. Celgene Corporation (NASDAQ:CELG) stock has just completed a technical pattern that projects further upside. Long term debt can be defined as the sum of all long term debt fields Celgene long term debt for the three Stock Screener. celgene stock